IRIS
NOBILI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.458
AS - Asia 1.363
EU - Europa 842
SA - Sud America 636
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
AN - Antartide 1
Totale 4.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.405
SG - Singapore 727
BR - Brasile 529
IE - Irlanda 325
VN - Vietnam 234
CN - Cina 214
SE - Svezia 199
IT - Italia 125
AR - Argentina 43
DE - Germania 41
HK - Hong Kong 40
RU - Federazione Russa 34
IN - India 32
ID - Indonesia 29
GB - Regno Unito 27
BD - Bangladesh 25
CA - Canada 25
EC - Ecuador 21
MX - Messico 20
AT - Austria 18
PL - Polonia 15
UA - Ucraina 12
PY - Paraguay 11
CO - Colombia 10
IQ - Iraq 10
TR - Turchia 10
ES - Italia 8
ZA - Sudafrica 8
UY - Uruguay 7
FI - Finlandia 6
LT - Lituania 6
MA - Marocco 6
PE - Perù 6
BE - Belgio 5
KE - Kenya 5
KR - Corea 5
PK - Pakistan 5
RO - Romania 5
VE - Venezuela 5
CZ - Repubblica Ceca 4
TN - Tunisia 4
UZ - Uzbekistan 4
AL - Albania 3
BH - Bahrain 3
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
EU - Europa 3
SA - Arabia Saudita 3
AM - Armenia 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
FR - Francia 2
IR - Iran 2
JO - Giordania 2
KZ - Kazakistan 2
NP - Nepal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
GI - Gibilterra 1
HN - Honduras 1
HU - Ungheria 1
JP - Giappone 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MU - Mauritius 1
MY - Malesia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PW - Palau 1
RS - Serbia 1
Totale 4.340
Salva come PNG Salva come JPEG
Città #
Singapore 556
Dublin 325
Princeton 172
Beijing 156
Dallas 137
Santa Clara 114
Altamura 90
Ho Chi Minh City 89
Jacksonville 81
Ashburn 58
Wilmington 56
São Paulo 47
Hanoi 46
Hong Kong 40
Los Angeles 40
Buffalo 33
Redondo Beach 33
New York 25
Chandler 22
Rio de Janeiro 22
Nuremberg 19
The Dalles 17
Norwalk 15
Curitiba 14
Chicago 13
London 13
Dong Ket 12
Guayaquil 10
Mexico City 10
Montreal 10
Haiphong 9
Chennai 8
Munich 8
Porto Alegre 8
Denver 7
Phoenix 7
Thái Bình 7
Vienna 7
Warsaw 7
Belo Horizonte 6
Boston 6
Brooklyn 6
Johannesburg 6
Milan 6
Montevideo 6
Mumbai 6
San Francisco 6
Stockholm 6
Uberlândia 6
Bauru 5
Brasília 5
Brussels 5
Fortaleza 5
Istanbul 5
Manchester 5
Nairobi 5
Salvador 5
Santa Fe 5
Seoul 5
Sorocaba 5
Toronto 5
Brno 4
Buenos Aires 4
Frankfurt am Main 4
Hangzhou 4
Hefei 4
Helsinki 4
José C. Paz 4
Osasco 4
Phủ Lý 4
Poplar 4
Recife 4
Romola 4
Santo André 4
São José dos Pinhais 4
Tashkent 4
Ankara 3
Aparecida de Goiânia 3
Araraquara 3
Atlanta 3
Bình Dương 3
Bắc Giang 3
Campinas 3
Campos dos Goytacazes 3
Caracas 3
Caruaru 3
Charlotte 3
Criciúma 3
Da Nang 3
Diadema 3
Guarulhos 3
Ha Long 3
Hyderabad 3
Hải Dương 3
Itajubá 3
Jakarta 3
João Pessoa 3
Lima 3
Lấp Vò 3
Macaé 3
Totale 2.595
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 122
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 109
Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents 91
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 86
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 85
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 82
A clinical-genetic score to identify surgically resected colorectal cancer patients benefiting from an adjuvant fluoropyrimidine-based therapy 80
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: A first insight 78
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 77
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy 75
Druggable targets in pancreatic adenocarcinoma 70
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 68
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds 68
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 67
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 65
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 64
Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? 64
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 62
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions 61
Specific markers, micro-environmental anomalies and tropism: opportunities for gold nanorods targeting of tumors in laser-induced hyperthermia 61
Cellular pharmacology of gemcitabine 60
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 60
Chronic inflammation in urothelial bladder cancer 60
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 59
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 58
Efficacy evaluation of plant products in the treatment of erectile dysfunction related to diabetes 58
Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer 58
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 57
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 56
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: A pilot study 56
HLA-G 3'UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment 55
Prognostic factors in primary and iterative surgery of colorectal liver metastases 55
Some suggestions from pk/pd principles to contain resistance in the clinical setting—focus on icu patients and gram-negative strains 54
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 54
Oxaliplatin plus Raltitrexed in the treatment of patients with advanced colorectal cancer: A phase II study 54
Proteomic analysis of the cytotoxic effects induced by the organogold(iii) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 53
Natural compounds for cancer treatment and prevention 53
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 52
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 52
Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2′-pyridyl)benzimidazole as ligand: Comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives 52
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer 52
PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients 52
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 51
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(ii) compounds with sulfur and phosphorus donors 51
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 51
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma 51
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma 51
Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? 50
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer 50
Size dependent biological profiles of PEGylated gold nanorods 49
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 48
Postoperative chemotherapy in resected gastric cancer: Results of a single center experience 48
Genomic and genetic alterations infuence the progression of gastric cancer 48
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 47
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 47
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, In combination with cisplatin In patients with advanced non-small-cell lung cancer 47
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 46
Oxaliplatinum and 5-fluorouracil in protracted infusion in the treatment of advanced colorectal cancer 46
Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy 45
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 45
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 44
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc 44
Vinorelbine in non-small cell lung cancer: Real-world data from a single-institution experience 43
Editorial: Multidrug resistance in cancer: Pharmacological strategies from basic research to clinical issues 43
Emerging drugs in refractory colorectal cancer 43
Gold compounds as anticancer agents: Chemistry, cellular pharmacology, and preclinical studies 43
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 43
Establishment and characterization of a new spontaneously immortalized ER -/PR -/HER2 + human breast cancer cell line, DHSF-BR16 43
Role of ATP-binding cassette transporters in cancer initiation and progression 42
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 42
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 42
The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways 40
Pharmacogenetics: Implementing personalized medicine 39
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 38
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 38
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge 38
Pharmacological strategies for overcoming multidrug resistance 37
Focus on biochemical and clinical predictors of response to immune checkpoint inhibitors in metastatic urothelial carcinoma: Where do we stand? 37
Increased Expression of VANGL1 is Predictive of Lymph Node Metastasis in Colorectal Cancer: Results from a 20-Gene Expression Signature 37
Exploring the biochemical mechanisms of cytotoxic gold compounds: A proteomic study 36
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer 36
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 35
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 32
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer 30
Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery 30
Maintenance in gastric cancer: New life for an old issue? 30
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 29
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties 28
Totale 4.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.427
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.427
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021316 0 0 0 0 0 227 13 8 14 13 14 27
2021/2022214 1 4 3 2 4 0 2 21 28 6 50 93
2022/2023568 98 98 79 1 3 147 68 21 44 6 3 0
2023/2024304 12 27 20 18 12 82 98 0 0 5 8 22
2024/20251.419 103 464 295 11 37 8 43 39 163 65 96 95
2025/20261.729 173 266 471 575 213 31 0 0 0 0 0 0
Totale 4.688